ClinicalTrials.gg
CompletedNCT01086267Updated Jun 27, 2016

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

A Phase 1/2 interventional study of BMS-908662 and BMS-908662 in Colorectal Cancer, sponsored by Bristol-Myers Squibb. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-27.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
164th of 185
17 · median 60
Started
2010
with 11 others
Phase 1/2
20 of 187
6 open now
Registered
78th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 164th largest by enrollment of the 185 interventional ones that give a count, is one of 12 that started in 2010, is one of 20 in phase 1/2, and was the 78th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when administered alone or in combination with cetuximab

Read the detailed description

Phase 1: Single Arm Study

Phase 2: Randomized Controlled, Parallel

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with K-RAS (codon 12 or 13) or B -RAF (V600E) mutation positive advanced or colorectal cancer who have or are refractory to 2 or more standard systemic anticancer regimes for metastatic disease, or are intolerant to existing therapies.
  • Histologic or cytologic confirmation of the diagnosis.
  • (ECOG) ≤ 1
  • Adequate organ \& marrow function.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled or significant cardiovascular disease.
  • Phase 2: Prior therapy with a RAF inhibitor.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    BMS-908662 (A1)

    Phase 1

    Drug: BMS-908662

  • Experimental
    Cetuximab (A1)

    Phase 1

    Drug: Cetuximab

  • Experimental
    BMS-908662 (B1)

    Phase 2

    Drug: BMS-908662

  • Experimental
    BMS-908662 + Cetuximab (B2)

    Phase 2

    Drug: BMS-908662 · Drug: Cetuximab

Interventions

  • Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously

  • Capsules, Oral, (TBD) mg, Q 12 h, Continuously

  • Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously

06

What researchers measure

Primary outcomes

  1. Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3

    Time frame: Assessments every 1-2 weeks while receiving study drug

Secondary outcomes

  1. Efficacy as determined by estimates of objective response rates and response duration

    Time frame: Efficacy measured at least every 8 weeks while receiving study drug

  2. Pharmacodynamics (PD) will be assessed by evaluating markers of RAS/RAF pathway activity

    Time frame: PD assessed during the first 4 weeks on study

  3. Pharmacokinetics (PK) for BMS-908662 as determined by minimum observed concentrations [Cmin].

    Time frame: PK measured during first 4 weeks on study

  4. Pharmacokinetics (PK) for BMS-908662 as determined by maximum observed concentrations [Cmax].

    Time frame: PK measured during first 4 weeks on study

  5. Pharmacokinetics (PK) for BMS-908662 as determined by time of maximum observed concentration [Tmax].

    Time frame: PK measured during first 4 weeks on study

  6. Pharmacokinetics (PK) for BMS-908662 as determined by area under the concentration-curve for one dosing interval [AUC(TAU)].

    Time frame: PK measured during first 4 weeks on study

  7. Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].

    Time frame: PK measured during first 4 weeks on study

07

Study locations

3 sites
  • Oncology Research Associates D/B/A
    Scottsdale, Arizona 85258, United States
  • Usc Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Local Institution
    Ottawa, Ontario K1H 1C3, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2010
First posted
Mar 15, 2010
Start
Jul 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results delay requested
Sep 23, 2015
Last update
Jun 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01086267
Responsible party
Sponsor
First posted
Mar 15, 2010
Start date
Jul 2010
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Jun 27, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BMS-908662 · Cetuximab

Start the discussion